Personalizing DNA Cancer Vaccines
Journal of Personalized Medicine · 02.10.2025 · 15 (10) · 474
DOI: 10.3390/jpm15100474 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 02.10.2025. Verfasst von Annie A Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 271 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute Specialized Program of Research Excellence (SPORE) in Cervical Cancer grant, National Institutes of Health, National Cancer Institute Specialized Program of Research Excellence (SPORE) in Cervical Cancer.
Abstract (Originalsprache)
Recent progress in tumor immunotherapy highlights the important role of the immune system in combating various cancers. Traditionally designed to protect against infectious diseases, vaccines are now being adapted to stimulate immune responses against tumor-specific neoantigens. Both preclinical studies and clinical trials have explored innovative approaches for identifying neoantigens and optimizing vaccine design, advancing the field of personalized oncology. Among these, DNA-based vaccines have become a particularly attractive approach for cancer immunotherapy. This evolution has been driven by improvements in molecular biology techniques, including more precise methods for detecting tumor-specific mutations, computational tools for predicting immunogenic antigens, and novel platforms for delivering nucleic acid vaccines. Personalized DNA vaccines are typically developed through a complex, multi-step process that involves sequencing a patient’s tumor, computational analysis to identify potential targets, and custom vaccine production. In this review, we examine the use of both shared tumor antigens and individualized neoantigens in cancer vaccine development. We outline strategies for neoantigen identification that provide insights into tumor-specific alterations. Furthermore, we highlight recent advances in DNA vaccine technologies, address the current limitations facing cancer vaccines, propose strategies to overcome these challenges, and consider key clinical and technical factors for successful implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
- Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
- Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
ORCID-Profile: Annie A Wu, Michelle Zhu, Arindam Bagga
Förderung
- NCI NIH HHS
- National Institutes of Health, National Cancer Institute Specialized Program of Research Excellence (SPORE) in Cervical Cancer grant
- National Institutes of Health, National Cancer Institute Specialized Program of Research Excellence (SPORE) in Cervical Cancer
Zitieren
APA
Wu, A. A., Peng, K., Vukovich, M., Zhu, M., Lin, Y., Bagga, A., Wu, T. C., & Hung, C. F. (2025). Personalizing DNA Cancer Vaccines. Journal of Personalized Medicine, 15(10), 474. https://doi.org/10.3390/jpm15100474
Vancouver
Wu AA, Peng K, Vukovich M, Zhu M, Lin Y, Bagga A, et al. Personalizing DNA Cancer Vaccines. Journal of Personalized Medicine. 2025;15(10):474. doi:10.3390/jpm15100474
BibTeX
@article{Wu2025,
author = {Wu, Annie A and Peng, Kaiqi and Vukovich, Melanie and Zhu, Michelle and Lin, Yuki and Bagga, Arindam and Wu, T C and Hung, Chien-Fu},
title = {Personalizing DNA Cancer Vaccines},
journal = {Journal of Personalized Medicine},
year = {2025},
volume = {15},
number = {10},
pages = {474},
doi = {10.3390/jpm15100474}
}
EUVIMED